nutlin 3

Known as: nutlin-3 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2005-2017
051020052017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
The renal cell carcinoma (RCC) is one of the top 10 cancers in USA. The renal tumors are highly angiogenic and are resistant to… (More)
Is this relevant?
2012
2012
Although TP53 mutations are rare in acute myeloid leukemia (AML), wild type p53 function is habitually annulled through… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2012
2012
Medulloblastomas account for 20% of pediatric brain tumors. With an overall survival of 40%-70%, their treatment is still a… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2011
Highly Cited
2011
Six p53 wild-type cancer cell lines from infrequently p53-mutated entities (neuroblastoma, rhabdomyosarcoma, and melanoma) were… (More)
Is this relevant?
2011
2011
Mutation of p53 is rare in Ewing's sarcoma (ES), suggesting that targeting and activation of wild-type p53 may be an effective… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2009
2009
Murine double minute 2 (MDM2) negatively regulates the activity of the tumor suppressor protein p53. Nutlin-3 is a MDM2 inhibitor… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
2009
2009
PURPOSE Seventy to eighty percent of rhabdomyosarcoma (RMS) tumors retain wild-type p53. The tumor suppressor p53 plays a central… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2008
2008
In pediatric acute lymphoblastic leukemia (ALL), overexpression of murine double minute 2 (MDM2) protein by leukemic cells is… (More)
Is this relevant?
2007
2007
Nutlin-3, a nongenotoxic activator of the p53 pathway, dose-dependently (range 0.1 to 10 micromol/L) inhibited the formation of… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2006
Highly Cited
2006
Deletions and/or mutations of p53 are relatively rare and late events in the natural history of B-cell chronic lymphocytic… (More)
  • table 1
  • figure 1
  • figure 2
  • table 2
  • figure 4
Is this relevant?